Healthcare provider profile · identity verified

Joann Suna, M.D.

Internal Medicine · NATICK, MA · NPI 1801854633

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	453	138
Lisinopril	Lisinopril	323	93
Amlodipine Besylate	Amlodipine Besylate	263	79
Levothyroxine Sodium	Levothyroxine Sodium	229	73
Omeprazole	Omeprazole	209	66
Metoprolol Succinate	Metoprolol Succinate	177	53
Losartan Potassium	Losartan Potassium	135	47
Rosuvastatin Calcium	Rosuvastatin Calcium	134	44
Simvastatin	Simvastatin	134	43
Valsartan	Valsartan	129	35
Alendronate Sodium	Alendronate Sodium	126	35
Gabapentin	Gabapentin	106	33
Metformin Hcl Er	Metformin Hcl	100	28
Hydrochlorothiazide	Hydrochlorothiazide	99	33
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	93	26
Eliquis	Apixaban	89	19
Sertraline Hcl	Sertraline Hcl	80	23
Alprazolam	Alprazolam	69	21
Metformin Hcl	Metformin Hcl	66	21
Citalopram Hbr	Citalopram Hydrobromide	63	18
Zolpidem Tartrate	Zolpidem Tartrate	62	18
Pravastatin Sodium	Pravastatin Sodium	58	22
Atenolol	Atenolol	50	19
Escitalopram Oxalate	Escitalopram Oxalate	50	13
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	50	16
Celecoxib	Celecoxib	47	11
Synthroid	Levothyroxine Sodium	46	13
Allopurinol	Allopurinol	43	12
Famotidine	Famotidine	43	14
Tramadol Hcl	Tramadol Hcl	41	13
Trazodone Hcl	Trazodone Hcl	41	14
Montelukast Sodium	Montelukast Sodium	40	11
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	40	29
Carvedilol	Carvedilol	39	13
Lorazepam	Lorazepam	38	26
Ozempic	Semaglutide	38	suppressed
Trulicity	Dulaglutide	38	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	36	17
Estradiol	Estradiol	36	suppressed
Paroxetine Hcl	Paroxetine Hcl	36	suppressed
Furosemide	Furosemide	35	17
Irbesartan	Irbesartan	35	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	35	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	34	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	31	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	31	14
Fluticasone Propionate	Fluticasone Propionate	30	14
Ipratropium Bromide	Ipratropium Bromide	30	suppressed
Clopidogrel	Clopidogrel Bisulfate	26	suppressed
Duloxetine Hcl	Duloxetine Hcl	26	suppressed
Spironolactone	Spironolactone	26	suppressed
Jardiance	Empagliflozin	25	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	23	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	23	suppressed
Clonazepam	Clonazepam	20	suppressed
Glipizide Er	Glipizide	20	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	19	suppressed
Naproxen	Naproxen	18	suppressed
Temazepam	Temazepam	18	suppressed
Ventolin Hfa	Albuterol Sulfate	18	suppressed
Meloxicam	Meloxicam	17	suppressed
Ondansetron Odt	Ondansetron	17	suppressed
Buspirone Hcl	Buspirone Hcl	16	suppressed
Diclofenac Sodium	Diclofenac Sodium	16	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	16	suppressed
Oxycodone Hcl	Oxycodone Hcl	16	suppressed
Ezetimibe	Ezetimibe	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Lidocaine	Lidocaine	14	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	14	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	14	suppressed
Bupropion Hcl Sr	Bupropion Hcl	13	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	13	suppressed
Ibuprofen	Ibuprofen	13	suppressed
Indapamide	Indapamide	13	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	13	suppressed
Acyclovir	Acyclovir	12	suppressed
Asa-Butalb-Caffeine-Codeine	Codeine/Butalbital/Asa/Caffein	12	suppressed
Diazepam	Diazepam	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Perphenazine	Perphenazine	12	suppressed
Potassium Citrate Er	Potassium Citrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error